China (Mainland)
Premiumsupplier
ALK-IN-27 CAS NO.2739866-40-9
- Min.Order: 100 Gram
- Payment Terms: L/C,T/T
- Available Specifications:
- Product Details
Keywords
- ALK-IN-27
- NVL-655
- (R)-1-chloro-3-ethyl-12-fluoro-10,16-dimethyl-3,10,16,18-tetrahydro-4,8-(metheno)benzo[l]dipyrazolo[3,4-g:4',3'-j][1]oxa[4]azacyclotetradecin-7-amine
Quick Details
- ProName: ALK-IN-27
- CasNo: 2739866-40-9
- Molecular Formula: C23H22ClFN6O
- Appearance: white powder
- Application: NVL-655 (ALK-in-27) is a novel, brain ...
- DeliveryTime: 2 months
- PackAge: fiber can
- Port: shanghai port
- ProductionCapacity: 100 Kilogram/Year
- Purity: 99%
- Storage: store at 2-8℃
- Transportation: air transport
- LimitNum: 100 Gram
- Related Substances: ＜0.1%
- Residue on Ignition: ＜0.1%
- Heavy Metal: ＜20ppm
- Valid Period: 2 years
Superiority
The quality of our products is guaranteed and the price is low！
Details
English name: ALK-IN-27 English synonym ALK-IN-27; (R) - 1 - chloro - 3 - baton rouge - 12 - fluoro - 10 - dimethyl - 23,10,16,18 - tetrahydro - 4, 8 - (metheno) benzo [l] dipyrazolo [3, 4 - g: 4, '3' - j] [1] oxa [4]azacyclotetradecin-7-amine; Chemicalbook (R) - 1 - chloro - 3 - baton rouge - 12 - fluoro - 10 - dimethyl - 23,10,16,18 - tetrahydro - 4, 8 - (metheno) benzo [l] dipyrazolo [3, 4 - g: 4 ' ,3'-j][1]oxa[4]azacyclotetradecin-7-amine
CAS number 2739866-40-9
Molecular formula C23H22ClFN6O
Molecular weight 452.91
The Predicted density was 1.46±0.1g/cm3(Temp:20°C; Press: 7 )
(Predicted) acidity coefficient (pKa) 7.11 + / - 0.40
(Predicted) forms a solid color white to rice white
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
|---|---|
| Solubility | Soluble in DMSO |
| Handling | Refer to MSDS |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
NVL-655 is a novel brain-osmotic ALK selective inhibitor designed to address unmet needs that exist in currently available ALK inhibitors, including therapeutic resistance, brain metastases, and off-target central nervous system (CNS) adverse effects associated with TRK inhibition (AE).